Nano-X Imaging Ltd. (NASDAQ:NNOX) saw its stock price collapse by nearly 45% on Thursday, closing at $0.8697, after the company withdrew its 2026 revenue guidance and disclosed that its existing cash reserves are not enough to sustain operations for the next twelve months. The dramatic sell-off erased roughly half of the company's market capitalization, which now stands at approximately $60.5 million.
Trading volume surged to about 17.8 million shares, representing roughly 26% of the company's outstanding shares, as investors reacted to the bleak financial update. The stock fluctuated between $0.75 and $1.17 during the session before settling at the lower end of the range.
Revenue Struggles and Cash Burn
While Nano-X reported a 53% increase in total first-quarter revenue to $4.311 million, the core imaging-system and OEM revenue amounted to a mere $167,000, only about 4% of the total. The bulk of revenue came from teleradiology services at $3.1 million and AI and software at $1.0 million. The company's flagship product, the Nanox.ARC system, has yet to generate meaningful sales.
The company's cash position has deteriorated significantly. As of March 31, 2026, Nano-X held $44.2 million in cash, deposits, and restricted deposits, down from $60.0 million at the end of December 2025. The first-quarter operating cash burn was $14.0 million, and after accounting for a short-term bank loan, net cash stood at roughly $27 million. At the current burn rate, that covers less than two quarters of operations.
Guidance Withdrawn
In April, Nano-X had reaffirmed a 2026 revenue target of $35 million, implying the need to generate about $30.7 million over the remaining three quarters, or roughly $10.2 million per quarter. However, with first-quarter imaging-system revenue at just $167,000, that target became unattainable. The company has now withdrawn its 2026 revenue goal and will no longer provide annual revenue guidance.
CEO Erez Meltzer acknowledged the challenges, stating that the company is "beginning to see revenue and increased scan utilization from the Nanox.ARC" but noted that the pace of commercialization depends on adoption, site readiness, construction, approvals, and partner deliveries.
Deployment Pipeline and Cost Cuts
Nano-X maintains a deployment pipeline of about 40 systems at various stages, most of which are not yet generating revenue. The company expects 21 additional systems to be installed under the Nanox Imaging Network in the coming months, and it has distribution agreements covering roughly 360 CapEx systems in the U.S. over the next two to three years.
To conserve cash, management has initiated cost-cutting measures, including the elimination of 15 jobs in Israel and reduced staff hours in other areas. Early signs in June suggest a lower burn rate. The company is also reviewing options for its South Korea operations, which could involve restructuring, a sale, or a potential shutdown.
Market Context and Risks
The market cap now trades at approximately 1.4 times the March cash balance and about 2.2 times the preliminary net cash figure, well below the reported shareholder equity of $126.3 million, which includes $57.4 million in intangibles and $30.6 million in property and equipment. The stock is effectively being valued as a cash-runway play, with investors pricing in the risk of further dilution or a potential restructuring.
Adding to the uncertainty, a securities class-action lawsuit was filed on June 12 in New Jersey, targeting disclosures related to the company's South Korea operations. Nano-X has not yet estimated potential losses and has made no accrual.
Despite the setbacks, the Nanox.ARC system is in commercial use at a RadNet Inc. (NASDAQ:RDNT) site, and management is exploring additional RadNet locations. However, as Meltzer noted, "commercialization in medical imaging takes time," and the third quarter is expected to be a period of implementation after onboarding partners in Q2.
